Chronic expression of monocyte chemoattractant protein‐1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice
- 1 May 2005
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 19 (7) , 761-772
Abstract
Increased central nervous system (CNS) levels of monocyte chemoattractant protein 1 [CC chemokine ligand 2 (CCL2) in the systematic nomenclature] have been reported in chronic neurological diseases such as human immunodeficiency virus type 1‐associated dementia, amyotrophic lateral sclerosis, and multiple sclerosis. However, a pathogenic role for CCL2 has not been confirmed, and there is no established model for the effects of chronic CCL2 expression on resident and recruited CNS cells. We report that aged (>6 months) transgenic (tg) mice expressing CCL2 under the control of the human glial fibrillary acidic protein promoter (huGFAP‐CCL2 hi tg + mice) manifested encephalopathy with mild perivascular leukocyte infiltration, impaired blood brain barrier function, and increased CD45‐immunoreactive microglia, which had morphologic features of activation. huGFAP‐CCL2 hi tg + mice lacking CC chemokine receptor 2 (CCR2) were normal, showing that chemokine action via CCR2 was required. Studies of cortical slice preparations using video confocal microscopy showed that microglia in the CNS of huGFAP‐CCL2 hi tg + mice were defective in expressing amoeboid morphology. Treatment with mutant CCL2 peptides, a receptor antagonist and an obligate monomer, also suppressed morphological transformation in this assay, indicating a critical role for CCL2 in microglial activation and suggesting that chronic CCL2 exposure desensitized CCR2 on microglia, which in the CNS of huGFAP‐CCL2 hi tg + mice, did not up‐regulate cell‐surface expression of major histocompatibility complex class II, CD11b, CD11c, or CD40, in contrast to recruited perivascular macrophages that expressed enhanced levels of these markers. These results indicate that huGFAP‐CCL2 hi tg + mice provide a useful model to study how chronic CNS expression of CCL2 alters microglial function and CNS physiology.—Huang, D., Wujek, J., Kidd, G., He, T. T., Cardona, A., Sasse, M. E., Stein, E. J., Kish, J., Tani, M., Charo, I. F., Proudfoot, A. E., Rollins, B. J., Handel, T., Ransohoff, R. M. Chronic expression of monocyte chemoattractant protein‐1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice. FASEB J . 19, 761–772 (2005)Keywords
Funding Information
- National Institutes of Health (3RO1 NS32151-09)
- Nancy Davis Foundation for Multiple Sclerosis
This publication has 62 references indexed in Scilit:
- Transfection With a Dominant-Negative Inhibitor of Monocyte Chemoattractant Protein-1 Gene Improves Cardiac Function After 6 Hours of Cold PreservationCirculation, 2003
- Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune EncephalomyelitisJournal of Experimental Medicine, 2000
- Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissueJournal of Neuroimmunology, 2000
- Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1Nature, 2000
- Confocal Imaging of Microglial Cell Dynamics in Hippocampal Slice CulturesMethods, 1999
- Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesionsJournal of Neuroimmunology, 1998
- Requirement for CD40 Ligand in Costimulation Induction, T Cell Activation, and Experimental Allergic EncephalomyelitisScience, 1996
- Microglia: a sensor for pathological events in the CNSTrends in Neurosciences, 1996
- Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes.Journal of Clinical Investigation, 1995
- Multiple Sclerosis: Distribution of T Cell Subsets Within Active Chronic LesionsScience, 1983